Uses for non-autologous mesenchymal stem cells

• US 7,029,666 B2
• Filed: 01/14/2002
• Issued: 04/18/2006
• Est. Priority Date: 03/13/1998
• Status: Expired due to Term

• Current Assignee: Mesoblast International Srl
• Original Assignee: Osiris Therapeutics Incorporated (Smith & Nephew PLC)
• Inventors: Mosca, Joseph D., McIntosh, Kevin R., Bruder, Scott P., Marshak, Daniel R.
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US10/046,530
• Publication Number:
  US 20020064519A1
• Time in Patent Office: 1,555 Days
• Field of Search: 435/325, 435/455, 424/93.21, 424/93.1
• US Class Current: 424/93.1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

Methods and devices using non-autologous mesenchymal stem cells comprising treating a recipient in need thereof with an effective amount of non-autologous mesenchymal stem cells, including methods and preparations for treating and regenerating connective tissue and enhancing bone marrow engraftment in an individual; and for using genetically engineered allogeneic human mesenchymal stem cells that carry within them genes of interest particularly for the expression of physiologically or pharmacologically active proteins in gene therapy for correction of genetic disorders or “rebuilding” proteins important in tissue repair.

Claims

1. A method for promoting muscle tissue growth in a human subject, comprising:

treating a human recipient in need of muscle tissue growth by administering, by infusion or direct injection, a therapeutically effective amount of allogeneic mesenchymal stem cells to said human recipient, wherein said allogeneic mesenchymal stem cells are obtained from a human donor and wherein a step of MHC matching of said human donor to the recipient is not employed prior to the administration of said allogeneic mesenchymal stem cells to said human recipient.

2. The method of claim 1, wherein the allogeneic human mesenchymal stem cells are recovered from human bone marrow and are administered to the human recipient in a cell preparation that is substantially free of blood cells.

3. The method of claim 2, wherein the cell preparation is administered in conjunction with a carrier for the cell preparation.

4. The method of claim 3, wherein the preparation is administered systemically.

5. The method of claim 3, wherein the preparation is are administered intravenously.

6. The method of claim 1, wherein the allogeneic human mesenchymal stem cells express incorporated genetic material of interest.

10. The method of claim 1 wherein said direct injection is direct injection into said muscle tissue.

7. A method of promoting connective tissue implantation in a recipient mammal comprising the steps of adhering allogeneic mesenchymal stem or progenitor cells onto the connective tissue surface of a prosthetic device and implanting into the recipient mammal the prosthetic device containing these mesenchymal cells under conditions suitable for differentiating the stem cells into the type of connective tissue needed for implantation and wherein said allogeneic mesenchymal stem or progenitor cells are obtained from a mammalian donor and wherein a step of MHC matching of said mammalian donor to a recipient is not employed prior to the administration of said allogeneic mesenchymal stem cells to a mammalian recipient.

8. The method of claim 7, wherein said recipient mammal is a human patient.

9. The method of claim 7, wherein said mesenchymal stem cells are human mesenchymal stem cells.